首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

2133931

2034年免疫療法和CAR:T細胞療法市場預測—按療法、適應症、給藥途徑、技術、最終用戶和地區分類的全球分析

Immunotherapy & CAR-T Cell Therapy Market Forecasts to 2034 - Global Analysis By Therapy Type, Indication, Administration Route, Technology, End User and By Geography

出版日期: 2026年09月01日 | 出版商:

Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，預計到 2026 年，全球免疫療法和 CAR-T 細胞療法市場規模將達到 68 億美元，並在預測期內以 14.9% 的複合年成長率成長，到 2034 年將達到 207 億美元。

免疫療法和CAR-T細胞療法是兩種創新療法，它們透過活化或調節免疫系統來針對癌細胞。免疫療法包括查核點抑制劑、單株抗體、治療性疫苗以及旨在增強抗腫瘤免疫力的相關技術。在CAR-T療法中，首先採集T細胞，對其進行基因改造使其能夠識別特定的腫瘤抗原，然後再將其重新輸注回患者體內。隨著精準醫療、生物標記鑑定、細胞製備、臨床研究以及提高治療安全性和有效性等方面的進步，這些療法在血液系統惡性腫瘤和新興固體癌治療領域的應用正在不斷擴展。

據美國食品藥物管理局（FDA）稱，其腫瘤卓越中心在2024年促成了89種癌症治療藥物和生物製藥的批准。其中包括19項新分子實體（NME）或生物製藥的上市許可申請，以及34項已核准產品的新適應症。這顯示該監管機構持續致力於支持癌症治療領域的創新。

癌症發生率上升和未滿足的治療需求

癌症發病率的不斷攀升推動了對創新免疫療法和CAR-T細胞療法的日益成長的需求。血液系統惡性腫瘤和其他困難腫瘤的診斷數量不斷增加，促使臨床醫生探索更具標靶性和持久性的治療方法。傳統癌症治療的局限性，例如抗藥性、復發和全身性副作用，進一步激發了人們對免疫療法的興趣。臨床證據的進步、適應症的擴大以及對腫瘤生物學認知的加深，也加速了個人化細胞療法的研發與應用。

高昂的治療成本和複雜的製造程序

高昂的治療費用和複雜的生產要求可能會阻礙免疫療法和CAR-T細胞療法的廣泛應用。 CAR-T療法涉及對每位患者進行個別化的細胞採集、基因改造、細胞增殖、品質評估和重複輸注，這需要大量的資源。專用的生產設施、專業人員、先進技術以及病患監測都會增加成本。保險報銷的限制和醫療預算的約束使得許多醫療機構難以獲得這些療法。因此，高昂的整體成本可能會阻礙其普及，並可能導致合格的患者和醫療機構無法廣泛獲得這些先進的細胞療法。

固體癌治療進展

固體癌研究的進展為免疫療法和CAR-T細胞療法帶來了巨大的潛力。儘管CAR-T療法在某些血液系統惡性腫瘤的治療中取得了顯著進展，但研究人員目前正致力於克服限制其在固體癌治療中療效的障礙。腫瘤抗原、修飾受體、聯合治療策略和標靶遞送技術的創新可望拓展CAR-T療法的治療應用範圍。如果這些方法能夠展現出持續的臨床療效，它們將顯著擴大潛在患者群體，並為製藥、生物技術和細胞治療公司創造新的商機。

監管和核准方面的挑戰

嚴格的監管標準對免疫療法和CAR-T細胞療法的研發構成重大挑戰。這些療法涉及複雜的生物學機制、基因工程流程、個人化生產以及安全性考量，需要廣泛的臨床和監管評估。臨床試驗、生產驗證或核准的延誤會導致研發成本增加和商業化進程延緩。隨著法律規範的不斷演變，企業可能面臨額外的合規義務。這些不確定性會降低投資吸引力，延遲產品上市，並減緩創新細胞療法和免疫療法惠及合格的患者的速度。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對免疫療法和CAR-T細胞療法活動造成了暫時性的影響，導致臨床試驗延遲、病患招募中斷、治療延誤、醫院收治能力下降。用於治療新冠感染疾病的資源分配、旅行限制和供應鏈中斷，進一步加劇了細胞採集、生產、物流和治療交付方面的挑戰。疫情期間，癌症患者獲得專科服務的機會有限。然而，新冠疫情也推動了遠端監測、分散式臨床試驗、數位化醫療解決方案以及更完善的生產策略的採用，隨著腫瘤服務和研究計畫的恢復，這些舉措促進了該領域的復甦。

在預測期內，單株抗體細分市場預計將佔據最大的市場佔有率。

由於單株抗體能夠選擇性地針對癌症相關抗原，預計在預測期內，單株抗體領域將佔據最大的市場佔有率。這些抗體可以抑制有害的訊號路徑、活化免疫機製或直接輔助清除惡性細胞。單株抗體在多種癌症類型中的廣泛應用、已確立的臨床證據以及與聯合治療的兼容性，都為其強大的市場地位做出了貢獻。抗體工程、標靶精準化和治療研發領域的持續進步，正在拓展其應用範圍，並進一步鞏固主導地位。

預計在預測期內，癌症研究機構板塊的複合年成長率將最高。

在預測期內，癌症研究機構預計將呈現最高的成長率，這主要得益於其對創新癌症療法的推進和評估所做出的重大貢獻。該領域的活動包括轉化研究、早期臨床試驗、生物標記研究和細胞療法開發。對新型免疫療法的關注，使研究人員能夠更有效地探索新的目標、聯合治療和基因修飾的免疫細胞技術。與製藥和生物技術公司不斷擴大的合作，正在加強研究基礎設施，並加快有前景的免疫療法和CAR-T細胞療法候選藥物進入臨床開發階段的步伐。

市佔率最大的地區：

在預測期內，北美預計將保持最大的市場佔有率，這得益於其先進的醫療保健體系、強大的癌症研究能力和眾多專業治療機構。該地區強大的生物技術產業和活躍的臨床研究環境正在推動先進癌症療法的研發和應用。製藥公司、學術機構和醫療機構之間的合作進一步加速了創新和商業化。此外，有利的保險報銷環境、個人化醫療日益普及以及專業細胞治療中心的覆蓋範圍擴大，都鞏固了該地區的領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健體系的不斷發展、對先進癌症療法的需求日益成長以及腫瘤學研究活動的活性化。生物技術能力的提升和專業細胞治療設施的建設正在增強該地區患者獲得治療的機會。製藥和生物技術公司也在亞洲主要國家拓展夥伴關係和臨床計畫。人們對個人化醫療的認知不斷提高、創新療法的可及性增強以及研究基礎設施的不斷完善，都為加速區域市場成長創造了有利環境。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要公司進行SWOT分析（最多3家公司）
區域細分
- 根據客戶要求，我們可以提供主要國家的市場估算、預測和複合年成長率計算（註：需進行可行性檢查）。
競爭性標竿分析
- 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第11章策略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第12章產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第13章：公司簡介

Gilead Sciences, Inc.
Bristol-Myers Squibb Company
Johnson & Johnson
Novartis AG
Legend Biotech
Autolus Therapeutics
Galapagos NV
Fate Therapeutics
AstraZeneca
Mustang Bio
Fosun Pharma
JW Therapeutics
IASO Biotherapeutics
Juventas Cell Therapy
CARsgen Therapeutics
Cellectis
Sorrento Therapeutics
Pfizer, Inc.

簡介目錄圖表

Product Code: SMRC39640

According to Stratistics MRC, the Global Immunotherapy & CAR-T Cell Therapy Market is accounted for $6.8 billion in 2026 and is expected to reach $20.7 billion by 2034 growing at a CAGR of 14.9% during the forecast period. Immunotherapy and CAR-T cell therapy represent innovative approaches that activate or engineer the immune system to target cancer cells. Immunotherapy encompasses checkpoint inhibitors, monoclonal antibodies, therapeutic vaccines, and related technologies designed to enhance antitumor immunity. CAR-T treatment involves collecting T cells, genetically engineering them to recognize selected tumor antigens, and returning them to the patient. Their adoption is growing across blood cancers and emerging solid-tumor applications, driven by advances in precision medicine, biomarker identification, cell manufacturing, clinical research, and efforts to improve therapeutic safety and effectiveness.

According to the FDA, its Oncology Center of Excellence facilitated 89 oncology drug and biologic product approvals in 2024, including 19 new molecular entities or biologics license applications and 34 new indications for previously approved products. This demonstrates continued regulatory activity supporting cancer-treatment innovation.

Market Dynamics:

Driver:

Rising cancer incidence and unmet treatment needs

The growing prevalence of cancer is strengthening the need for innovative immunotherapy and CAR-T cell treatments. Rising diagnoses across blood cancers and challenging tumor types are encouraging clinicians to consider therapies that can deliver more targeted and lasting responses. Limitations associated with conventional cancer treatments, including treatment resistance, relapse, and adverse systemic effects, are increasing interest in immune-based technologies. Advances in clinical evidence, broader therapeutic applications, and deeper knowledge of tumor biology are also accelerating the development and adoption of personalized cellular therapies.

Restraint:

High treatment costs and complex manufacturing

Expensive treatment and complicated manufacturing requirements can restrict the expansion of immunotherapy and CAR-T cell therapy. CAR-T therapy involves personalized cell collection, genetic engineering, cellular expansion, quality assessment, and reinfusion, requiring substantial resources. Dedicated manufacturing facilities, specialized staff, sophisticated technologies, and patient monitoring add further costs. Limited reimbursement and healthcare budgets can make these therapies difficult to access in many settings. As a result, high overall expenses may constrain adoption and prevent eligible patients and healthcare institutions from widely utilizing advanced cellular treatment options.

Opportunity:

Expansion into solid tumor treatment

Growing research into solid tumors offers considerable opportunities for immunotherapy and CAR-T cell therapy. CAR-T treatments have achieved notable progress in selected hematological cancers, while researchers are now working to address barriers that limit effectiveness against solid tumors. Innovations involving tumor antigens, engineered receptors, combination treatment strategies, and targeted delivery could expand therapeutic applications. If these approaches demonstrate consistent clinical benefits, they could significantly enlarge the potential patient pool and support new commercial opportunities for pharmaceutical, biotechnology, and cell-therapy companies.

Threat:

Regulatory and approval challenges

Stringent regulatory standards pose a significant challenge to immunotherapy and CAR-T cell therapy development. Their complex biological mechanisms, genetic engineering processes, individualized production, and safety considerations require extensive clinical and regulatory assessment. Delays involving trials, manufacturing validation, or approvals can raise development expenses and extend commercialization schedules. Evolving regulatory frameworks may introduce further compliance obligations for companies. These uncertainties can reduce investment attractiveness, delay product launches, and slow the availability of innovative cellular and immune-based treatments to eligible patients.

Covid-19 Impact:

The COVID-19 outbreak temporarily affected immunotherapy and CAR-T cell therapy activities through postponed clinical studies, disrupted patient enrollment, delayed treatments, and reduced hospital capacity. Resource allocation toward COVID-19 care, transportation restrictions, and supply-chain difficulties created additional challenges for cell collection, production, logistics, and treatment delivery. Cancer patients experienced limited access to specialized services during the pandemic. Nevertheless, COVID-19 encouraged greater use of remote monitoring, decentralized trials, digital healthcare solutions, and stronger manufacturing strategies, helping the sector recover as oncology services and research programs resumed.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is expected to account for the largest market share during the forecast period due to their ability to selectively target cancer-associated antigens. They can interfere with harmful signaling pathways, activate immune mechanisms, or directly support the elimination of malignant cells. Their widespread use across different cancers, established clinical foundation, and compatibility with combination therapies contribute to their strong market presence. Ongoing advances in antibody engineering, targeting precision, and treatment development are expanding their applications and reinforcing their leading role in modern immunotherapy.

The cancer research institutes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cancer research institutes segment is predicted to witness the highest growth rate as they contribute significantly to the advancement and assessment of innovative cancer therapies. Their activities include translational research, early clinical investigations, biomarker studies, and development of cellular treatments. Concentration on emerging immunotherapy approaches enables researchers to investigate novel targets, combination therapies, and engineered immune-cell technologies more effectively. Growing partnerships with pharmaceutical and biotechnology organizations are enhancing research infrastructure and helping accelerate the progression of promising immunotherapy and CAR-T cell therapy candidates into clinical development.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by sophisticated healthcare systems, extensive cancer research capabilities, and numerous specialized treatment facilities. Its strong biotechnology sector and active clinical research environment encourage the development and adoption of advanced cancer treatments. Partnerships between pharmaceutical firms, academic organizations, and healthcare institutions further facilitate innovation and commercialization. In addition, supportive reimbursement environments, increasing acceptance of personalized medicine, and expanding access to specialized cellular therapy centers reinforce the region's dominant position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by developing healthcare systems, rising demand for advanced cancer treatments, and stronger oncology research activity. Growing biotechnology capabilities and specialized cell-therapy facilities are improving regional treatment availability. Pharmaceutical and biotechnology organizations are also expanding partnerships and clinical programs throughout key Asian countries. Increasing awareness of personalized therapies, better access to innovative treatments, and expanding research infrastructure are collectively establishing a favorable environment for accelerated regional market growth.

Key players in the market

Some of the key players in Immunotherapy & CAR-T Cell Therapy Market include Gilead Sciences, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Legend Biotech, Autolus Therapeutics, Galapagos NV, Fate Therapeutics, AstraZeneca, Mustang Bio, Fosun Pharma, JW Therapeutics, IASO Biotherapeutics, Juventas Cell Therapy, CARsgen Therapeutics, Cellectis, Sorrento Therapeutics and Pfizer, Inc.

Key Developments:

In December 2025, Pfizer Inc. announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited, a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management.

In May 2025, Novartis has signed a strategic agreement with Shanghai Pharma to help sell the Swiss company's mature ophthalmic products in China. Novartis will leverage Shanghai Pharma's omni-channel integrated marketing services and broad market coverage capabilities to accelerate the reach of some Novartis drugs for ocular infections and glaucoma in smaller territories not currently targeted by Novartis.

Therapy Types Covered:

Monoclonal Antibodies
Immune Checkpoint Inhibitors
Cancer Vaccines
Cytokines & Interleukins
CAR-T Cell Therapy
Other Cell-Based Immunotherapies

Indications Covered:

Hematologic Malignancies
Solid Tumors
Autoimmune Disorders
Infectious Diseases

Administration Routes Covered:

Intravenous
Intratumoral
Oral

Technologies Covered:

Gene-Modified Cell Therapy
Non-Gene Modified Cell Therapy
Oncolytic Virus Therapy
Bispecific Antibodies

End Users Covered:

Hospitals
Cancer Research Institutes
Specialty Clinics
Academic & Research Organizations

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Immunotherapy & CAR-T Cell Therapy Market, By Therapy Type

5.1 Monoclonal Antibodies
5.2 Immune Checkpoint Inhibitors
5.3 Cancer Vaccines
5.4 Cytokines & Interleukins
5.5 CAR-T Cell Therapy
5.6 Other Cell-Based Immunotherapies

6 Global Immunotherapy & CAR-T Cell Therapy Market, By Indication

6.1 Hematologic Malignancies
6.2 Solid Tumors
6.3 Autoimmune Disorders
6.4 Infectious Diseases

7 Global Immunotherapy & CAR-T Cell Therapy Market, By Administration Route

7.1 Intravenous
7.2 Intratumoral
7.3 Oral

8 Global Immunotherapy & CAR-T Cell Therapy Market, By Technology

8.1 Gene-Modified Cell Therapy
8.2 Non-Gene Modified Cell Therapy
8.3 Oncolytic Virus Therapy
8.4 Bispecific Antibodies

9 Global Immunotherapy & CAR-T Cell Therapy Market, By End User

9.1 Hospitals
9.2 Cancer Research Institutes
9.3 Specialty Clinics
9.4 Academic & Research Organizations

10 Global Immunotherapy & CAR-T Cell Therapy Market, By Geography

10.1 North America
- 10.1.1 United States
- 10.1.2 Canada
- 10.1.3 Mexico
10.2 Europe
- 10.2.1 United Kingdom
- 10.2.2 Germany
- 10.2.3 France
- 10.2.4 Italy
- 10.2.5 Spain
- 10.2.6 Netherlands
- 10.2.7 Belgium
- 10.2.8 Sweden
- 10.2.9 Switzerland
- 10.2.10 Poland
- 10.2.11 Rest of Europe
10.3 Asia Pacific
- 10.3.1 China
- 10.3.2 Japan
- 10.3.3 India
- 10.3.4 South Korea
- 10.3.5 Australia
- 10.3.6 Indonesia
- 10.3.7 Thailand
- 10.3.8 Malaysia
- 10.3.9 Singapore
- 10.3.10 Vietnam
- 10.3.11 Rest of Asia Pacific
10.4 South America
- 10.4.1 Brazil
- 10.4.2 Argentina
- 10.4.3 Colombia
- 10.4.4 Chile
- 10.4.5 Peru
- 10.4.6 Rest of South America
10.5 Rest of the World (RoW)
- 10.5.1 Middle East
  - 10.5.1.1 Saudi Arabia
  - 10.5.1.2 United Arab Emirates
  - 10.5.1.3 Qatar
  - 10.5.1.4 Israel
  - 10.5.1.5 Rest of Middle East
- 10.5.2 Africa
  - 10.5.2.1 South Africa
  - 10.5.2.2 Egypt
  - 10.5.2.3 Morocco
  - 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

11.1 Industry Value Network and Supply Chain Assessment
11.2 White-Space and Opportunity Mapping
11.3 Product Evolution and Market Life Cycle Analysis
11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

12.1 Mergers and Acquisitions
12.2 Partnerships, Alliances, and Joint Ventures
12.3 New Product Launches and Certifications
12.4 Capacity Expansion and Investments
12.5 Other Strategic Initiatives

13 Company Profiles

13.1 Gilead Sciences, Inc.
13.2 Bristol-Myers Squibb Company
13.3 Johnson & Johnson
13.4 Novartis AG
13.5 Legend Biotech
13.6 Autolus Therapeutics
13.7 Galapagos NV
13.8 Fate Therapeutics
13.9 AstraZeneca
13.10 Mustang Bio
13.11 Fosun Pharma
13.12 JW Therapeutics
13.13 IASO Biotherapeutics
13.14 Juventas Cell Therapy
13.15 CARsgen Therapeutics
13.16 Cellectis
13.17 Sorrento Therapeutics
13.18 Pfizer, Inc.

簡介目錄圖表

List of Tables

Table 1 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Therapy Type (2023-2034) ($MN)
Table 3 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
Table 4 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Immune Checkpoint Inhibitors (2023-2034) ($MN)
Table 5 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Cancer Vaccines (2023-2034) ($MN)
Table 6 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Cytokines & Interleukins (2023-2034) ($MN)
Table 7 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By CAR-T Cell Therapy (2023-2034) ($MN)
Table 8 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Other Cell-Based Immunotherapies (2023-2034) ($MN)
Table 9 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Indication (2023-2034) ($MN)
Table 10 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Hematologic Malignancies (2023-2034) ($MN)
Table 11 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Solid Tumors (2023-2034) ($MN)
Table 12 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Autoimmune Disorders (2023-2034) ($MN)
Table 13 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Infectious Diseases (2023-2034) ($MN)
Table 14 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Administration Route (2023-2034) ($MN)
Table 15 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Intravenous (2023-2034) ($MN)
Table 16 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Intratumoral (2023-2034) ($MN)
Table 17 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Oral (2023-2034) ($MN)
Table 18 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Technology (2023-2034) ($MN)
Table 19 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Gene-Modified Cell Therapy (2023-2034) ($MN)
Table 20 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Non-Gene Modified Cell Therapy (2023-2034) ($MN)
Table 21 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Oncolytic Virus Therapy (2023-2034) ($MN)
Table 22 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Bispecific Antibodies (2023-2034) ($MN)
Table 23 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By End User (2023-2034) ($MN)
Table 24 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Hospitals (2023-2034) ($MN)
Table 25 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Cancer Research Institutes (2023-2034) ($MN)
Table 26 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Specialty Clinics (2023-2034) ($MN)
Table 27 Global Immunotherapy & CAR-T Cell Therapy Market Outlook, By Academic & Research Organizations (2023-2034) ($MN)